EWTX

Edgewise Therapeutics, Inc. [EWTX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

EWTX Stock Summary

Top 10 Correlated ETFs

EWTX

Top 10 Correlated Stocks

EWTX

In the News

EWTX Financial details

Company Rating
-
Market Cap
1.52B
Income
-97.06M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
88
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-8.38
Forward P/E
-
PEG
-0.2
P/S
-
P/B
2.41
P/C
-
P/FCF
-8.17
Quick Ratio
17.73
Current Ratio
18.23
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.53
EPS next Y
-
EPS next Q
-
EPS this Y
441.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.63%
-
-
-
-
SMA20
-11.54%
SMA50
-14.81%
SMA100
-34.29%
Inst Own
-
Inst Trans
-
ROA
-27%
ROE
-26%
ROC
-0.35%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.12-20.69
52W High
+1.88%
52W Low
+307.5%
RSI
30
Rel Volume
0.81
Avg Volume
959.07K
Volume
776.26K
Perf Week
-10.64%
Perf Month
-24.82%
Perf Quarter
-32.82%
Perf Half Y
-21.9%
-
-
-
-
Beta
0.15
-
-
Volatility
1%, 1.91%
Prev Close
-7.39%
Price
20.375
Change
-9.77%

Something similar

Top by Market Cap
AMZ.DE
TSLA
META
BRH.DE
1YD.DE
Top Correlated ETFs
TUR.PA
LTUR.DE
BLDG
Top Correlated Stocks
HUSQ-A.ST
HUSQ-B.ST
0OA7.L
MGPI
PHI
Similar Market Cap
000637.SZ
GEMU.PA
600538.SS
BYIT.L
PSEC

Company Profile

Healthcare Biotechnology
  • Volume Average 959.07K
  • Market Capitalization 1.52B
  • Employee 88
  • CEO Dr. Kevin Koch Ph.D.
  • Headquarters Boulder,CO,US
  • IPO Date 2021-03-26
  • Website https://www.edgewisetx.com

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.